Loading…
Employees: 250
Size Applied Nutrition (APN.L) is a United Kingdom Health Care company (Pharmaceuticals: Other) with a market value of $1.01B, the 214th largest of 363 United Kingdom companies the cockpit tracks. Shares closed at £301.50 on 6 Nov 2026.
Performance Over six months the shares gained 41.5%, against -16.4% for the median peer and +3.6% for the United Kingdom market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 24.3% over the last twelve months (peer median +3.1%).
Valuation It trades at 24.2× forward earnings against a peer median of 18.6× (7th most expensive of 16).
Next results Next results expected around 16 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | £107M | £86.2M | £60.8M | £35.0M |
| Revenue growth | — | +24% | +42% | +74% | — |
| Gross profit | n/a | £48.2M | £40.4M | £26.5M | £13.6M |
| EBITDA | n/a | £30.9M | £25.8M | £18.5M | £10.4M |
| Net income | n/a | £21.1M | £18.7M | £13.8M | £8.21M |
| Free cash flow | n/a | £15.2M | £6.28M | £7.62M | £6.18M |
| Capital expenditure | n/a | £1.00M | £1.06M | £1.00M | £294,000 |
| Total debt | n/a | £3.00M | £1.80M | £2.06M | £1.12M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | APN.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.9% | -5.2% | 3rd highest of 21 |
| 6-month return | +41.5% | -16.4% | 3rd highest of 21 |
| Distance from 52-week high | -15.3% | -34.9% | 6th highest of 21 |
| Revenue growth (TTM) | +24.3% | +3.1% | 6th highest of 20 |
| Forward P/E | 24.2× | 18.6× | 7th most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | 24.2× | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 193.0× | n/a | n/a |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 9.7× | n/a | n/a |
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.09B | -10% | -5% | 4% | 18.3× | 1.5% | +7.9% |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 51.5× | 25.8% | +13.4% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 29.6× | 4.0% | +18.5% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | n/a | 3.6% | -1.3% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 16.9× | 14.7% | +15.6% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 37.7× | 11.4% | -3.9% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 15.6× | 2.1% | +26.7% |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | n/a | 1.8% | +4.8% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | 7.2× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | n/a | 4.9% | +13.5% |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | n/a | n/a | n/a |
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% | +5.5% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% | +60.2% |